![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Viropharma Incorporated (MM) | NASDAQ:VPHM | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 49.98 | 0 | 01:00:00 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
|
|
|
|
SCHEDULE TO
TENDER OFFER STATEMENT UNDER SECTION 14(D)(1)
OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
VIROPHARMA INCORPORATED
(Name of Subject Company (Issuer))
|
|
VENUS NEWCO, INC.
|
|
SHIRE PHARMACEUTICAL HOLDINGS IRELAND LIMITED
|
|
(Names of Filing Persons (Offeror))
|
|
Common Stock, Par Value $0.002 Per Share
(Title of Class of Securities)
|
|
928241108
(Cusip Number of Class of Securities)
|
|
Michael Garry
Shire Pharmaceutical Holdings Ireland Limited
5 Riverwalk, Citywest Business Campus,
Dublin 24, Ireland
+353 1 4297700
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Persons)
|
|
Copies to:
George R. Bason, Jr.
William J. Chudd
Davis Polk & Wardwell
450 Lexington Avenue
New York, New York 10017
Telephone: (212) 450-4000
|
|
x
|
Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.
|
Check the appropriate boxes below to designate any transactions to which the statement relates:
|
|
x
|
third-party tender offer subject to Rule 14d-1.
|
o
|
issuer tender offer subject to Rule 13e-4.
|
o
|
going-private transaction subject to Rule 13e-3.
|
o
|
amendment to Schedule 13D under Rule 13d-2.
|
1.
|
driving optimum performance of our marketed (in-line) products – for patients today; and
|
2.
|
building our pipeline through both research & development and business development activities – for patients in the future.
|
·
|
Shire’s proposed acquisition of ViroPharma may not be consummated due to the occurrence of an event, change or other circumstances that gives rise to the termination of the merger agreement;
|
·
|
a governmental or regulatory approval required for the proposed acquisition of ViroPharma may not be obtained, or may be obtained subject to conditions that are not anticipated, or another condition to the closing of the proposed acquisition may not be satisfied;
|
·
|
ViroPharma may be unable to retain and hire key personnel and/or maintain its relationships with customers, suppliers and other business partners pending the consummation of the proposed acquisition by Shire, or ViroPharma’s business may be disrupted by the proposed acquisition, including increased costs and diversion of management time and resources;
|
·
|
difficulties in integrating ViroPharma into Shire may lead to greater costs and lower integration benefits than anticipated;
|
1 Year Viropharma Incorporated (MM) Chart |
1 Month Viropharma Incorporated (MM) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions